Richard Small; Anthony DeFino , 2025-05-09 15:30:00
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Richard Small, CEO of Neurotech Pharmaceuticals, provides an update on Encelto for macular telangiectasia type 2.
Ahead of the encapsulated cell therapy’s June launch following its FDA approval earlier this year, the company is educating retina specialists as well as the wider eye care community on macular telangiectasia and Encelto (revakinagene taroretcel-lwey).
“We are actually preparing to launch the product next month,” Small said.
Published by:
